Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck, Pfizer in diabetes deal

Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) partnered to co-develop and co-commercialize worldwide Pfizer's

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE